VitaNova Life Sciences (VNOV) Current Deferred Revenue (2025)
VitaNova Life Sciences (VNOV) reported Current Deferred Revenue of $4286.0 for Q4 2025, down 60.22% quarter-over-quarter from $10775.0 in Q3 2025.
VitaNova Life Sciences (VNOV) Current Deferred Revenue (2025) Analysis & Trends
VitaNova Life Sciences has reported Current Deferred Revenue for 1 years, with the latest figure at $4286.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn |
| 10 | VitaNova Life Sciences | - | - | 316,343.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | 4,286.00 |
| Jul 31, 2025 | 10,775.00 |